Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload

References

• Ifudu O, Macey LJ, Friedman EA. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients. ASAIO J. 1995;41:M426–30.
   PubMedGoogle Scholar
• Tanhehco YC, Berns JS. Red blood cell transfusion risks in patients with end-stage renal disease. Semin Dial. 2012;25:539–44.
   PubMed Web of Science ®Google Scholar
• Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology 2012;115:635–49.
   Web of Science ®Google Scholar
• Menis M, Izurieta HS, Anderson SA, Kropp G, Holness L, Gibbs J, et al. Outpatient transfusions and occurrence of serious noninfectious transfusion-related complications among US elderly, 2007–2008: utility of large administrative databases in blood safety research. Transfusion 2012;52:1968–76.
   PubMed Web of Science ®Google Scholar
• Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17:120–62.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Individualizing decision-making – resurrecting the doctor-patient relationship in the anemia debate. Clin J Am Soc Nephrol. 2010;5:1340–6.
   PubMed Web of Science ®Google Scholar
• Winchester JF. Management of iron overload in dialysis patients. Semin Nephrol. 1986;6( Suppl 1):22–6.
   PubMed Web of Science ®Google Scholar
• Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, et al. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1089–97.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminum chelating drugs. Toxicol Lett. 1995;80:1–18.
   PubMed Web of Science ®Google Scholar
• Kan WC, Chien CC, Wu CC, Su SB, Hwang JC, Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010;25:1604–8.
   PubMed Web of Science ®Google Scholar
• Agarwal MB. Deferasirox: oral, once daily iron chelator – an expert opinion. Indian J Pediatr. 2010;77:185–91.
   PubMed Web of Science ®Google Scholar
• Taher A. Iron overload in thalassemia and sickle cell disease. Semin Hematol. 2005;42:S5–9.
   PubMed Web of Science ®Google Scholar
• Cancado R, Olivato MC, Bruniera P, Szarf G, de Moraes Bastos R, Rezende Melo M, et al. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients. Acta Haematol. 2012;128:113–8.
   PubMed Web of Science ®Google Scholar
• Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120:970–7.
   PubMed Web of Science ®Google Scholar
• List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30:2134–9.
   PubMed Web of Science ®Google Scholar
• Hohneker JA. Exjade (deferasirox): boxed warning. In: MedWatch: The FDA Safety Information and Adverse Event Reporting Program, 2010.
   Google Scholar
• Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25:2376–8.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455–62.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. [Accessed 2013 May 20] Common terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009; Revised Version 4.03 June 14, 2010 (Vol. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf).
   Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2( Suppl):279–335.
   Web of Science ®Google Scholar
• Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87–93.
   PubMed Web of Science ®Google Scholar
• Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803–11.
   PubMed Web of Science ®Google Scholar
• Heath AL, Fairweather-Tait SJ. Health implications of iron overload: the role of diet and genotype. Nutr Rev. 2003;61:45–62.
   PubMed Web of Science ®Google Scholar
• Sengoelge G, Sunder-Plassmann G, Hörl WH. Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr. 2005;15:105–10.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Tsubakihara Y. Limiting iron supplementation for anemia in dialysis patients – the Basis for Japan's conservative guidelines. Semin Dial. 2011;24:269–71.
   PubMed Web of Science ®Google Scholar
• Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17( Suppl 2):25–9.
   PubMed Web of Science ®Google Scholar
• Deira J, Diego J, Martínez R, Oyarbide A, González A, Díaz H, et al. Comparative study of intravenous ascorbic acid versus low-dose desferrioxamine in patients on hemodialysis with hyperferritinemia. J Nephrol. 2003;16:703–9.
   PubMed Web of Science ®Google Scholar
• Tsai CW, Yang FJ, Huang CC, Kuo CC, Chen YM. The administration of deferasirox in an iron-overloaded dialysis patient. Hemodial Int. 2012;17:131–3.
   PubMed Web of Science ®Google Scholar
• Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynyk JK. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton). 2013;18:188–93.
   PubMed Web of Science ®Google Scholar
• Cappellini MD. Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag. 2007;3:291–9.
   PubMedGoogle Scholar
• Yusuf B, McPhedran P, Brewster UC. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis. 2008;52:587–90.
   PubMed Web of Science ®Google Scholar
• Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, et al. Deferasirox treatment for myelodysplastic syndromes: ‘real-life’ efficacy and safety in a single-institution patient population. Ann Hematol. 2012;91:1345–9.
   PubMed Web of Science ®Google Scholar
• Aucella F, Vigilante M, Scalzulli P, Musto P, Crisetti A, Modoni S, et al. Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients. Nephrol Dial Transplant. 1998;13:1194–9.
   PubMed Web of Science ®Google Scholar
• Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95:1308–16.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97(9):1364–71.
   PubMed Web of Science ®Google Scholar
• Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94(2):288–99.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Smeets M, Feelders RA, van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol. 1993;89(2):57–60.
   PubMed Web of Science ®Google Scholar
• Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92(2):191–8.
   PubMed Web of Science ®Google Scholar
• Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70–4.
   PubMed Web of Science ®Google Scholar
• Garadah TS, Mahdi N, Kassab S, Abu-Taleb A, Shoroqi I, Alawadi AH. The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major. Eur J Haematol. 2011;87:267–73.
   PubMed Web of Science ®Google Scholar